In children, idiopathic nephrotic syndrome (NS) generally responds well to treatment with corticosteroids, but long-term use of steroids in children can produce adverse effects (AEs) such as growth impairment and hypertension. Calcineurin inhibitors, too, are associated with AEs, including toxicity and diabetes. Rituximab has been proposed as an option for difficult-to-treat childhood-onset NS, and a recent study evaluated the efficacy and safety of a single dose of rituximab in this setting.
In children, idiopathic nephrotic syndrome (NS) generally responds well to treatment with corticosteroids, but long-term use of steroids in children can produce adverse effects (AEs) such as growth impairment and hypertension. Calcineurin inhibitors, too, are associated with AEs, including toxicity and diabetes. Rituximab has been proposed as an option for difficult-to-treat childhood-onset NS, and a recent study evaluated the efficacy and safety of a single dose of rituximab in this setting.
The study, a multicenter, open-label trial conducted in Korean patients with childhood-onset NS, involved patients aged under 24 years who were either drug-dependent for more than 2 years or who were intolerant to standard treatment.
The study’s design involved a randomized controlled trial (RCT) for drug-dependent patients and a single-arm study for patients whose disease was resistant to conventional treatment. In the RCT, patients were randomly assigned to receive either rituximab (n = 40) or standard treatment (n = 21), and in the single-arm study, all patients (n = 23) received rituximab in addition to their pre-enrollment treatment.
The primary end points of the study were the rate of retaining remission at 6 months in the RCT and the rate of remission within 6 months of starting rituximab in the single-arm study.
In the RCT, at 6 months, 74.3% of rituximab-treated patients were at remission, while 68.7% of standard therapy patients in the control group were in relapse (P = .003). The median duration of remission in the rituximab group was 9 months versus 2.9 months in the standard therapy group.
In the single-arm study, within 6 months of starting rituximab, 9 patients achieved either partial (n = 2) or complete (n = 7) remission.
In all patients treated with rituximab, CD19-positive B cells were depleted within 2 weeks of rituximab treatment. However, relapse after rituximab was not always linked with B-cell recovery; 4 patients had depleted B cells at the time of NS relapse.
In total, 50.8% of patients had infusion reactions to rituximab, and 5 of these patients discontinued infusion (all 5 patients were able to tolerate subsequent rituximab administrations, however). A total of 21 patients reported infections, and 45 experienced any AE. One patient died during the study, but the death was not attributable to rituximab therapy, the investigators concluded.
“Our study laid one more piece of evidence that [rituximab] can be safe and effective in patients with childhood-onset, medication-dependent NS,” wrote the authors, adding that controlled studies are warranted to determine the optimal dosing and interval for rituximab administration in patients with hard-to-treat NS.
Reference
Anh YH, Kim SH, Han KH, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine (Baltimore). 2018;97:e13158. doi: 10.1097/MD.0000000000013157.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.